home-page-logo

From Concept to Clinic
to the Commercial Market.

YOUR RADIOPHARMACEUTICAL DEVELOPMENT PARTNER.

At CPDC we are working with our partners to discover, develop and distribute the next generation of imaging agents and targeted radiotherapeutics for the detection and treatment of human diseases.

What Are Radiopharmaceuticals?

Radiopharmaceuticals are a special class of drugs. They’re sometimes called molecular imaging probes, contrast agents, tracers or radiotherapeutics.

Radiopharmaceuticals contain a radioactive isotope and they are used to both diagnose and treat disease.  Millions of patients receive radiopharmaceuticals annually for a wide variety of medical procedures ranging from the assessment of cardiac function to staging and treatment of cancer.

CPDC Announces First Patient Dosed in a Phase 3 Clinical Trial of a Prostate Cancer Diagnostic Imaging Product, [18F]PSMA-1007

Hamilton, Ontario, February 24, 2021 – The Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, is announcing today that the first patient has been dosed and imaged in a Phase 3 trial for [18F]PSMA-1007. This diagnostic imaging product is a positron-emitting tomography (PET) agent that

Do you love radiopharmaceuticals as much as we do?

CPDC is always looking for exceptional people to strengthen our team.

Join Our Team

For more information contact us at: